-
1
-
-
49449117755
-
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methyl-b enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor
-
18620382 10.1021/jm800566m 1:CAS:528:DC%2BD1cXosVGrtL4%3D
-
Harris PA, Boloor A, Cheung M et al (2008) Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino] -2-methyl-b enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51:4632-4640
-
(2008)
J Med Chem
, vol.51
, pp. 4632-4640
-
-
Harris, P.A.1
Boloor, A.2
Cheung, M.3
-
2
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
20100962 10.1200/JCO.2009.23.9764 1:CAS:528:DC%2BC3cXktF2lt78%3D
-
Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061-1068
-
(2010)
J Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
-
3
-
-
84861098484
-
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial
-
22595799 10.1016/S0140-6736(12)60651-5
-
van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879-1886
-
(2012)
Lancet
, vol.379
, pp. 1879-1886
-
-
Van Der Graaf, W.T.1
Blay, J.Y.2
Chawla, S.P.3
-
4
-
-
67449164582
-
Phase i trial of pazopanib in patients with advanced cancer
-
19509175 10.1158/1078-0432.CCR-08-2740 1:CAS:528:DC%2BD1MXntlOitr4%3D
-
Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220-4227
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4220-4227
-
-
Hurwitz, H.I.1
Dowlati, A.2
Saini, S.3
Savage, S.4
Suttle, A.B.5
Gibson, D.M.6
Hodge, J.P.7
Merkle, E.M.8
Pandite, L.9
-
5
-
-
77958498524
-
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in patients with advanced solid tumors
-
20881954 10.1038/clpt.2010.158 1:CAS:528:DC%2BC3cXhtlWmurjL
-
Goh BC, Reddy NJ, Dandamudi UB et al (2010) An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 88:652-659
-
(2010)
Clin Pharmacol Ther
, vol.88
, pp. 652-659
-
-
Goh, B.C.1
Reddy, N.J.2
Dandamudi, U.B.3
-
6
-
-
79952596398
-
Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects
-
21395644 10.1111/j.1365-2125.2010.03845.x 1:CAS:528:DC%2BC3MXltVKrtL0%3D
-
Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D (2011) Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 71:522-527
-
(2011)
Br J Clin Pharmacol
, vol.71
, pp. 522-527
-
-
Abbas, R.1
Hug, B.A.2
Leister, C.3
Burns, J.4
Sonnichsen, D.5
-
7
-
-
4644287353
-
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
-
15138710 10.1007/s00280-004-0832-z 1:CAS:528:DC%2BD2cXntV2htr0%3D
-
Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R, Seiberling M (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54:290-294
-
(2004)
Cancer Chemother Pharmacol
, vol.54
, pp. 290-294
-
-
Dutreix, C.1
Peng, B.2
Mehring, G.3
Hayes, M.4
Capdeville, R.5
Pokorny, R.6
Seiberling, M.7
-
8
-
-
77949369418
-
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors
-
20108303 10.1002/cncr.24927 1:CAS:528:DC%2BC3cXktFGgsLc%3D
-
Johnson FM, Agrawal S, Burris H et al (2010) Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116:1582-1591
-
(2010)
Cancer
, vol.116
, pp. 1582-1591
-
-
Johnson, F.M.1
Agrawal, S.2
Burris, H.3
-
9
-
-
80051553376
-
Clinical pharmacokinetics of tyrosine kinase inhibitors: Focus on pyrimidines, pyridines and pyrroles
-
21827214 10.2165/11593320-000000000-00000
-
Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50:551-603
-
(2011)
Clin Pharmacokinet
, vol.50
, pp. 551-603
-
-
Di Gion, P.1
Kanefendt, F.2
Lindauer, A.3
Scheffler, M.4
Doroshyenko, O.5
Fuhr, U.6
Wolf, J.7
Jaehde, U.8
-
10
-
-
0346734217
-
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study
-
14687806 10.1111/j.1572-0241.2003.08783.x 1:CAS:528:DC%2BD3sXpvVahs7o%3D
-
Miner P Jr, Katz PO, Chen Y, Sostek M (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98:2616-2620
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 2616-2620
-
-
Miner, Jr.P.1
Katz, P.O.2
Chen, Y.3
Sostek, M.4
-
11
-
-
77955807815
-
Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib
-
20498287 10.1177/0091270009346061 1:CAS:528:DC%2BC3cXhtVCmsL3J
-
Yin OQ, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, Schran H (2010) Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 50:960-967
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 960-967
-
-
Yin, O.Q.1
Gallagher, N.2
Fischer, D.3
Demirhan, E.4
Zhou, W.5
Golor, G.6
Schran, H.7
-
12
-
-
80955128532
-
Risk of high-grade liver toxicity with pazopanib in patients with cancer: A meta-analysis
-
Kapadia S, Hapani S, Wu S (2011) Risk of high-grade liver toxicity with pazopanib in patients with cancer: a meta-analysis. J Clin Oncol 29(suppl):abstract 4595
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
, pp. 4595
-
-
Kapadia, S.1
Hapani, S.2
Wu, S.3
-
13
-
-
0028357256
-
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole
-
8181191 10.1038/clpt.1994.60 1:STN:280:DyaK2c3js1ynsA%3D%3D
-
Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485
-
(1994)
Clin Pharmacol Ther
, vol.55
, pp. 481-485
-
-
Olkkola, K.T.1
Backman, J.T.2
Neuvonen, P.J.3
-
14
-
-
10744232330
-
The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
-
12814957 10.1124/dmd.31.7.815 1:CAS:528:DC%2BD3sXltFalu70%3D
-
Bjornsson TD, Callaghan JT, Einolf HJ et al (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 815-832
-
-
Bjornsson, T.D.1
Callaghan, J.T.2
Einolf, H.J.3
-
15
-
-
78449297407
-
A phase i study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors
-
20980999 10.1038/clpt.2010.199 1:CAS:528:DC%2BC3cXhsVegu7bE
-
Heath EI, Chiorean EG, Sweeney CJ et al (2010) A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 88:818-823
-
(2010)
Clin Pharmacol Ther
, vol.88
, pp. 818-823
-
-
Heath, E.I.1
Chiorean, E.G.2
Sweeney, C.J.3
-
16
-
-
0036024209
-
Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects
-
12144580 10.1046/j.1365-2036.2002.01292.x 1:CAS:528:DC%2BD38XntVCjsrg%3D
-
Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N (2002) Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 16:1301-1307
-
(2002)
Aliment Pharmacol Ther
, vol.16
, pp. 1301-1307
-
-
Warrington, S.1
Baisley, K.2
Boyce, M.3
Tejura, B.4
Morocutti, A.5
Miller, N.6
-
17
-
-
78249247114
-
The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers
-
20955444 10.1111/j.1365-2036.2010.04469.x 1:CAS:528:DC%2BC3cXhsFanu7fF
-
Wilder-Smith C, Rohss K, Bokelund Singh S, Sagar M, Nagy P (2010) The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers. Aliment Pharmacol Ther 32:1249-1256
-
(2010)
Aliment Pharmacol Ther
, vol.32
, pp. 1249-1256
-
-
Wilder-Smith, C.1
Rohss, K.2
Bokelund Singh, S.3
Sagar, M.4
Nagy, P.5
|